Find Lawyers Today, Get Legal Help.
Home >> Legal News >> RECALLS AND SAFETY ALERTS CAUTION ON BARACLUDE THERAPY FOR CERTAIN HBV PATIENTS
FDA News
BACK TO LAWYER CENTRAL LEGAL NEWS CENTER
RECALLS AND SAFETY ALERTS CAUTION ON BARACLUDE THERAPY FOR CERTAIN HBV PATIENTS
November 7, 2007
Bristol-Myers Squibb has notified healthcare professionals about a new boxed warning for the antiviral drug Baraclude (entecavir). Baraclude is approved to treat certain patients with chronic hepatitis B.
The boxed warning says that patients infe...Related FDA Stories:
- Recalls and Safety Alerts Sudden Hearing Loss from Erectile Dysfunction Dru..
- Recalls and Safety Alerts Recall of Sprint Fidelis Cardiac Leads..
- Recalls and Safety Alerts Possible Cancer Risk with Lantus..
Additional Legal Resources:
Complete the Form Below and Talk to Experienced Lawyers
